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Following the publication of our article [1], we noticed
that Dr. David LeBrun had inadvertently been omitted
from the author list. DL declares he has no conflicts of
interest. The author list has now been corrected and the
amended authors’ contributions included below.
AG performed the majority of experiments, analyzed
the data, and drafted the manuscript. VH provided
MDA231 and MDASrc ezrin KD and EZR/WT-expressing
cell lines and contributed to the design of experiments.
AS performed the TMA staining for Src/Ezrin, image
analysis, clinical outcome correlations, and VEGF-A/-C
western blots. DL supervised AS in establishing and opti-
mizing the quantification of Src/ezrin in histopathological
tissue samples by multi-channel immunofluorescence.
MH assisted with the aortic rings experiment and analysis.
NL assisted in quantification of angio/lymphangiogenic
activity in tumour xenograft H&E sections. KN assisted in
design and interpretation of aortic ring assay and analysis.
YM collected the clinical outcome data for the in-house
human breast cancer cohort and assisted in analysis and
interpretation of clinical correlative studies. SS assessed
the tumours in our breast cancer cohort and oversaw the
construction, staining, and analysis of all TMA-related
experiments. BEE conceived the project, supervised exper-
iments & analysis, and contributed to writing of the final
manuscript.
All authors have made substantial contribution to the
design of experiments, data analysis, and drafting of the
manuscript. All authors have reviewed and approved the
final version of this manuscript and agree to be account-
able for all aspects of the work presented herein.* Correspondence: elliottb@queensu.ca
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